MASH and type 2 diabetes create a destructive liver-pancreas feedback loop, but emerging therapies including GLP-1 agonists and dual incretin agents show promise in treating both conditions simultaneously.
Liver-pancreas feedback loopMASH and type 2 diabetes create a self-reinforcing cycle where liver damage worsens blood sugar control and high blood sugar worsens liver disease — emerging therapies aim to break this cycle at multiple points.
What the researchers found
MASH and T2DM share a bidirectional feedback loop: impaired hepatic insulin signaling (from fatty liver) worsens blood glucose control, while chronic hyperglycemia and insulin resistance further drive liver inflammation and fibrosis. Key cellular players include hepatocytes, Kupffer cells (liver macrophages), hepatic stellate cells (which produce scar tissue), and pancreatic β-cells.
Emerging therapies targeting multiple pathways simultaneously show the most promise: GLP-1 receptor agonists and dual incretin agents address both metabolic and liver inflammation, while PPAR modulators, thyroid hormone receptor beta agonists (like resmetirom), FXR agonists, and FGF analogues target distinct but overlapping mechanisms. Non-coding RNAs were identified as important regulators of lipid metabolism and inflammation in both diseases.
Why it matters
MASH and type 2 diabetes frequently coexist, with each condition worsening the other. Historically, they've been treated by different specialists using different drugs. The recognition that synergistic therapies — drugs that simultaneously improve both liver disease and metabolic control — could break the destructive feedback loop represents a major shift in treatment philosophy. This is especially relevant as the MASH treatment landscape transforms with multiple new drug classes entering clinical use.
How the study worked
This is a narrative review synthesizing molecular, cellular, and clinical evidence on the overlap between MASH and type 2 diabetes. The author examined the biological mechanisms connecting the two diseases and surveyed current and emerging therapeutic approaches, including both pharmacological and lifestyle interventions.
What this study cannot tell us
As a narrative review, this paper summarizes existing knowledge without generating new data or performing systematic analysis. The therapeutic landscape is rapidly evolving, and some emerging therapies discussed may have limited clinical evidence. The review focuses on molecular mechanisms and clinical advances but does not provide head-to-head comparisons between therapeutic approaches or specific treatment algorithms.
How to read the evidence
This is a narrative review providing a comprehensive overview of molecular mechanisms and therapeutic strategies. While it draws on clinical trial data for emerging therapies, it does not perform systematic review or meta-analysis. The evidence quality varies by topic — some therapies discussed have strong RCT support while others remain in early-stage development.
When this study was published
Published in 2025, this review is highly current and captures the latest advances in a rapidly evolving therapeutic landscape, including recently approved drugs like resmetirom and ongoing trials of dual incretin agents.
The bigger picture
This review captures a pivotal moment in metabolic medicine where the traditional siloed approach to treating diabetes and liver disease separately is giving way to integrated therapeutic strategies. The convergence of GLP-1 receptor agonists (from diabetes), resmetirom (from hepatology), and dual/triple incretin agonists (from metabolic disease) reflects a broader trend toward treating metabolic syndrome as an interconnected system rather than a collection of individual conditions.
Questions still open
- Which combination of emerging therapies will prove most effective for patients with both MASH and type 2 diabetes?
- Can non-coding RNA-based therapeutics eventually be developed to directly target the shared molecular pathways in MASH and diabetes?
- How should precision medicine approaches stratify patients to determine optimal treatment for their specific MASH-diabetes phenotype?
Common questions
Why do fatty liver disease and type 2 diabetes often occur together?
Can GLP-1 drugs treat both diabetes and fatty liver disease at the same time?
Read the original research
Synergistic therapeutic strategies for metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: molecular insights and clinical advances.
Frontiers in endocrinology, 16, 1753393
Citation
Zhu, Bo. (2025). Synergistic therapeutic strategies for metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: molecular insights and clinical advances.. Frontiers in endocrinology, 16, 1753393. https://doi.org/10.3389/fendo.2025.1753393